Tesaglitazar
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Oct 1, 2005 → Dec 1, 2006
NCT ID
NCT00300105About Tesaglitazar
Tesaglitazar is a phase 3 stage product being developed by AstraZeneca for Type 2 Diabetes. The current trial status is terminated. This product is registered under clinical trial identifier NCT00300105. Target conditions include Type 2 Diabetes.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00300105 | Phase 3 | Terminated |
| NCT00252837 | Phase 3 | Terminated |
| NCT00252876 | Phase 3 | Terminated |
| NCT00229710 | Phase 3 | Terminated |
| NCT00252772 | Phase 3 | Terminated |
| NCT00261417 | Phase 2 | Terminated |
Competing Products
20 competing products in Type 2 Diabetes